Etrasimod (Velsipity, Pfizer) is indicated for 'people 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy, or a biological agent'.
The dosage schedule will be available in the summary of product characteristics for etrasimod.
The company has a commercial arrangement. This makes etrasimod available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.